Even in the ETI epoch, surgery may still play a crucial role in managing CF-CRS patients, particularly in those not eligible for CFTR modulator therapy or experiencing severe disease not adequately controlled with medical therapy alone. This evidence concerns the gene CFTR and cystic fibrosis.